{"id":612926,"date":"2026-09-11T04:25:41","date_gmt":"2026-09-11T04:25:41","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/612926\/anca-vasculitis-clinical-trial-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight.html"},"modified":"2026-09-11T04:25:41","modified_gmt":"2026-09-11T04:25:41","slug":"anca-vasculitis-clinical-trial-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/612926\/anca-vasculitis-clinical-trial-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight.html","title":{"rendered":"ANCA Vasculitis Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788946144.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"ANCA Vasculitis Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788946144.jpg\" alt=\"ANCA Vasculitis Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight\" width=\"225\" height=\"135\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The ANCA Vasculitis clinical trial analysis report delivers important insights into ongoing research of 12+ pipeline ANCA Vasculitis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/div>\n<p style=\"text-align: justify\"><strong>(Albany, US) September 10, 2026-<\/strong> DelveInsight&rsquo;s &ldquo;<strong>ANCA Vasculitis Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify\"><strong>Curious about the latest updates in the ANCA Vasculitis Pipeline? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anca-vasculitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/anca-vasculitis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the ANCA Vasculitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li><strong><em>On September 04, 2026, Novartis Pharmaceuticals<\/em><\/strong> initiated a phase 2 study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA).<\/li>\n<li><strong><em>On September 02, 2026, Fate Therapeutics<\/em><\/strong> conducted a Phase 1\/2, open-label trial designed to evaluate the safety, pharmacokinetics (PK), anti-B-cell activity, and clinical activity of FT839 in participants with moderate-to-severe ANCA-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc).<\/li>\n<li>DelveInsight&rsquo;s ANCA Vasculitis Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for ANCA Vasculitis treatment.<\/li>\n<li>The leading ANCA Vasculitis companies include <strong><em>Staidson (Beijing) Biopharmaceutical, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., <\/em><\/strong>and others.<\/li>\n<li>Promising ANCA Vasculitis therapies include <strong><em>Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisolone, Rituximab, Mycophenolate Mofetil<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Want to know which companies are leading innovation in ANCA Vasculitis? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anca-vasculitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">ANCA Vasculitis Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">The ANCA Vasculitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The ANCA Vasculitis Pipeline Report also highlights the unmet needs with respect to the ANCA Vasculitis.<\/p>\n<p style=\"text-align: justify\"><strong>ANCA Vasculitis Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Antineutrophilic cytoplasmic antibody (ANCA) associated Vasculitis are a heterogeneous group of rare autoimmune conditions that causes an inflammation of blood vessels with various manifestations. It includes three main diseases, which are granulomatosis with polyangiitis (GPA; formerly known as Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome), and microscopic polyangiitis (MPA). Other ANCA-associated diseases are drug-induced vasculitis and renal limited vasculitis. Signs and symptoms of ANCA vasculitis include fatigue, fever, weight loss, and muscle or joint pain. It can cause specific organ involvement, leading to respiratory issues like cough or shortness of breath and kidney problems such as blood in the urine. Skin manifestations, including rashes or ulcers, may also occur. Additionally, patients may experience nerve damage, resulting in numbness or weakness, and gastrointestinal symptoms like abdominal pain or diarrhea.<\/p>\n<p style=\"text-align: justify\"><strong>ANCA Vasculitis Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li><strong>BDB-001: Staidson (Beijing) Biopharmaceutical<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify\">BDB-001 is an investigational anti-complement C5a monoclonal antibody being developed by Staidson (Beijing) Biopharmaceuticals for the treatment of ANCA-associated vasculitis (AAV). By selectively neutralizing C5a, a key mediator of complement activation that drives neutrophil priming, inflammation, and vascular injury in AAV, BDB-001 aims to suppress disease activity while potentially reducing patients&#8217; dependence on high-dose glucocorticoids. The therapy has previously demonstrated an acceptable safety profile and pharmacodynamic inhibition of circulating C5a in early clinical studies, supporting its continued development. BDB-001 is currently being evaluated in a Phase III for the treatment of ANCA Associated Vasculitis.<\/p>\n<ul style=\"text-align: justify\">\n<li><strong>Sparsentan: Travere Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify\">Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.<\/p>\n<p style=\"text-align: justify\"><strong>If you&rsquo;re tracking ongoing ANCA Vasculitis Clinical trials, this press release is a must-read @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anca-vasculitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">ANCA Vasculitis Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>The ANCA Vasculitis Pipeline report provides insights into:-<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of ANCA Vasculitis with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ANCA Vasculitis Treatment.<\/li>\n<li>ANCA Vasculitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>ANCA Vasculitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ANCA Vasculitis market.<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>ANCA Vasculitis Companies<\/strong><\/p>\n<p style=\"text-align: justify\"><strong><em>Staidson (Beijing) Biopharmaceutical, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and <\/em><\/strong>others.<\/p>\n<p style=\"text-align: justify\"><strong>ANCA Vasculitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>ANCA Vasculitis Products have been categorized under various Molecule types such as,<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>From emerging drug candidates to competitive intelligence, the ANCA Vasculitis Pipeline Report covers it all @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anca-vasculitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">ANCA Vasculitis Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Scope of the ANCA Vasculitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Coverage- Global<\/li>\n<li>ANCA Vasculitis Companies- <strong><em>Staidson (Beijing) Biopharmaceutical, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and<\/em><\/strong> others.<\/li>\n<li>ANCA Vasculitis Therapies- <strong><em>Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisolone and Rituximab, Mycophenolate Mofetil, Avacopan<\/em><\/strong>, and others.<\/li>\n<li>ANCA Vasculitis Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>ANCA Vasculitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Discover what&rsquo;s next for the ANCA Vasculitis Treatment landscape in this detailed analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anca-vasculitis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">ANCA Vasculitis Emerging Drugs and Major Players<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>ANCA Vasculitis: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>ANCA Vasculitis &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>BDB-001: Staidson (Beijing) Biopharmaceutical<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Sparsentan: Travere Therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>ANCA Vasculitis Key Companies<\/li>\n<li>ANCA Vasculitis Key Products<\/li>\n<li>ANCA Vasculitis- Unmet Needs<\/li>\n<li>ANCA Vasculitis- Market Drivers and Barriers<\/li>\n<li>ANCA Vasculitis- Future Perspectives and Conclusion<\/li>\n<li>ANCA Vasculitis Analyst Views<\/li>\n<li>ANCA Vasculitis Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p class=\"caps\"><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=anca-vasculitis-clinical-trial-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/anca-vasculitis-pipeline-insight\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/anca-vasculitis-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=anca-vasculitis-clinical-trial-pipeline-emerging-therapies-and-key-developments-shaping-the-treatment-landscape-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The ANCA Vasculitis clinical trial analysis report delivers important insights into ongoing research of 12+ pipeline ANCA Vasculitis drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) September 10,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/612926"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=612926"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/612926\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=612926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=612926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=612926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}